Guangzhou Virotech Pharmaceutical Co., Ltd.

Researchers are testing an experimental intravenous biologic called M1-c6v1 in adults with locally advanced or metastatic solid tumors that have not responded to standard treatment. The Phase I trial gives escalating doses to a small group of participants to check safety, find th…

Researchers are running a Phase I trial of VRT106, an experimental biological therapy given by intravenous drip, in adults with locally advanced or metastatic solid tumors that have not responded to standard treatment. The trial enrolls about 12 people aged 18 to 75. It aims to f…

This study tests whether adding the drug VRT106 to standard radiation therapy can help control a rare, fast-growing brain tumor called diffuse midline glioma (including DIPG) in adults. About 10 participants aged 18 to 75 will receive the combination treatment. The main goal is t…

This clinical trial is testing a new drug called VRT106 combined with two other drugs (camrelizumab and apatinib) in people with advanced liver cancer that has not responded to prior immunotherapy. The study will enroll 66 participants and aims to see if the combination is safe a…

This study tests a new drug, VRT106, in 42 adults whose glioblastoma (a fast-growing brain tumor) has returned or worsened. The main goals are to check safety, find the best dose, and see if it helps shrink tumors or extend life. Participants receive VRT106 by injection and are c…

This early-phase study tests a modified virus called VRT106, which is injected directly into tumors to kill cancer cells. It involves 30 adults with advanced solid tumors that haven't responded to standard treatments. The main goal is to check safety and find the best dose, while…